Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
NCT01516762 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2014-07-14
Summary
This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC patients diagnosed with symptomatic bone metastasis and to collect additional short and long term safety data on the product.
Conditions
- Prostatic Neoplasms
Interventions
- DRUG
-
Radium-223 dichloride (BAY88-8223)
One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bayer Study Director · Bayer
Eligibility
- Min Age
- 18 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone
NCT03304418 ·Status: COMPLETED ·Phase: PHASE2
-
A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
NCT02034552 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones
NCT04521361 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Learn More About How Radium-223 is Being Used With Other Treatments in European Patients Who Have Not Received Radium-223 Before
NCT04587427 ·Status: COMPLETED
-
Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms
NCT02043678 ·Status: COMPLETED ·Phase: PHASE3
-
Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223
NCT03223597 ·Status: COMPLETED
-
Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer
NCT02141438 ·Status: COMPLETED
-
Post-eRADicAte - A Long Term Follow up of Subjects That Completed the eRADicAte Study (NCT 02097303)
NCT03414437 ·Status: UNKNOWN
-
Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC
NCT03432949 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases
NCT01934790 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis
NCT02507570 ·Status: COMPLETED ·Phase: PHASE2
-
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
NCT02582749 ·Status: TERMINATED ·Phase: PHASE2
-
Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer
NCT02204943 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer
NCT03230734 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
NCT04489719 ·Status: RECRUITING
-
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
NCT03737370 ·Status: COMPLETED ·Phase: PHASE1
-
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
NCT03361735 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population
NCT02518698 ·Status: COMPLETED
-
Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC
NCT02463799 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment Satisfaction With Ra-223 in Japan
NCT03315260 ·Status: COMPLETED
-
PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn
NCT04256993 ·Status: COMPLETED
-
Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223
NCT03223727 ·Status: COMPLETED
-
Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone
NCT04232761 ·Status: COMPLETED
-
Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients
NCT01565746 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Learn More About How Radium-223 Affects the Quality of Life of Colombian Patients With Prostate Cancer That Has Not Responded to Testosterone Lowering Treatment and Has Spread to the Bones, and to Better Understand Its Safety
NCT04681144 ·Status: COMPLETED